Exelixis's CABOSUN Rises For Cabometyx After Bristol's Opdivo/Yervoy Letdown

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Exelixis's Cabometyx has been submitted for accelerated approval in first-line kidney cancer, adding to the drug's good news after disappointing interim Phase III results for the Bristol-Myers Opdivo/Yervoy combo.

Digital illustration of Cancer cell in colour background

Exelixis Inc. completed its submission of a supplemental new drug application (sNDA) for US FDA accelerated approval of Cabometyx (cabozantinib) in previously untreated advanced renal cell carcinoma (RCC) on Aug. 16, a day after the drug's competitive position was bolstered by disappointing interim Phase III results for Bristol-Myers Squibb Co.'s Opdivo (nivolumab) and Yervoy (ipilimumab).

South San Francisco-based Exelixis is seeking early approval for its tyrosine kinase inhibitor (TKI) – which blocks MET, AXL and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.